Lenvatinib and Adebrelimab Combined With GEMOX in the Perioperative Treatment of Potentially Resectable Intrahepatic Cholangiocarcinoma

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 30, 2024

Primary Completion Date

April 20, 2025

Study Completion Date

May 30, 2025

Conditions
Intrahepatic Cholangiocarcinoma
Interventions
DRUG

Lenvatinib

Lenvatinib(oral,12mg once daily if body weight ≥60Kg; Body weight \< 60Kg, 8mg/ day); Adebrelimab(intravenous drip,1200mg once every 3 weeks); GEMOX(intravenous drip,Gemcitabine 1000mg/m2, 2 times every 3 weeks d1+d8; intravenous drip,Oxaliplatin, 100mg/m2, was given every 3 weeks)

Trial Locations (1)

Unknown

Tongji Hospital, Wuhan

All Listed Sponsors
lead

Zhiyong Huang

OTHER

NCT06417606 - Lenvatinib and Adebrelimab Combined With GEMOX in the Perioperative Treatment of Potentially Resectable Intrahepatic Cholangiocarcinoma | Biotech Hunter | Biotech Hunter